Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morpheus-Melanoma: Treatment Combinations in Melanoma
NCT05116202Phase 2Completed
- Sponsor
- Roche
- Start
- Feb 2022
- Primary completion
- Sep 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of tobemstomig in melanoma, sponsored by Roche. Started Feb 2022; status: completed.
02
Drugs
tobemstomig
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05116202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05116202.